Skip to main content
Erschienen in:

01.03.2005 | Leitthema

Mammakarzinom—Standards der Versorgung heute und morgen

verfasst von: Prof. Dr. C. Thomssen

Erschienen in: Die Onkologie | Ausgabe 3/2005

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Mammakarzinom ist eine der häufigsten Krebserkrankungen in unserer Gesellschaft. Inzidenz, Risikofaktoren, Prävention, Früherkennung, Heilungsrate nach Diagnosestellung und Prognose nach Metastasierung unterliegen einem steten Wandel. Riskofaktoren sind die Verlängerung der hormonellen Exposition, das zunehmende Alter bei der ersten Geburt, fettreiche Ernährung, fehlende körperliche Aktivität und längere Lebenserwartung. Eine medikamentöse Prävention kann in Zukunft vielleicht in manchen Situationen das Erkrankungsrisiko senken. Vorstufen und Frühformen des Mammkarzinoms können durch eine geeignete Früherkennung (Mammographie-Screening) entdeckt werden. Die mammakarzinombedingte Mortalität kann dadurch nachweislich erheblich gesenkt werden.
Die Prognose nach Diagnosestellung hat sich v. a. durch den Einsatz effektiverer adjuvanter Therapieformen verbessert. Eine adäquate Behandlung des Primärtumors durch Operation und ggf. Bestrahlung soll die lokale Ausbreitung des Tumors kontrollieren. Die Entwicklung neuer Medikamente in der Chemotherapie und in der endokrinen Therapie und mehr Wissen über ihren Einsatz gewährleisten eine effektivere und z. T. auch nebenwirkungsärmere adjuvante Behandlung.
Literatur
3.
Zurück zum Zitat Peto R, Boreham J, Clarke M, Davies C, Beral V (2000) UK and USA breast cancer deaths down 25% in year 2000 at ages 2069 years Volume Correspondence. Lancet 355:20 Peto R, Boreham J, Clarke M, Davies C, Beral V (2000) UK and USA breast cancer deaths down 25% in year 2000 at ages 2069 years Volume Correspondence. Lancet 355:20
4.
Zurück zum Zitat Hsieh CC, Trichopoulos D, Katsouyanni K, Yuasa S (1990) Age at menarche, age at menopause, height and obesity as risk factors for breast cancer: associations and interactions in an international case-control study. Int J Cancer 46:796–800 Hsieh CC, Trichopoulos D, Katsouyanni K, Yuasa S (1990) Age at menarche, age at menopause, height and obesity as risk factors for breast cancer: associations and interactions in an international case-control study. Int J Cancer 46:796–800
5.
Zurück zum Zitat Monninkhof EM, van der Schouw YT, Peeters PH (1999) Early age at menopause and breast cancer: are leaner women more protected? A prospective analysis of the Dutch DOM cohort. Breast Cancer Res Treat 55:285–291 Monninkhof EM, van der Schouw YT, Peeters PH (1999) Early age at menopause and breast cancer: are leaner women more protected? A prospective analysis of the Dutch DOM cohort. Breast Cancer Res Treat 55:285–291
6.
Zurück zum Zitat Beral V (2003) Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419–427CrossRefPubMed Beral V (2003) Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419–427CrossRefPubMed
7.
Zurück zum Zitat Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F (2004) Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer [Epub ahead of print] Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F (2004) Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer [Epub ahead of print]
8.
Zurück zum Zitat Collaborative Group on Hormonal Factors in Breast Cancer (2002) Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 360:187–195, review Collaborative Group on Hormonal Factors in Breast Cancer (2002) Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 360:187–195, review
9.
Zurück zum Zitat Abou-Dakn M, Scheele M, Strecker JR (2003) Does breast-feeding prevent breast cancer? Zentralbl Gynakol 125:48–52, review Abou-Dakn M, Scheele M, Strecker JR (2003) Does breast-feeding prevent breast cancer? Zentralbl Gynakol 125:48–52, review
10.
Zurück zum Zitat Lahmann PH, Hoffmann K, Allen N et al. (2004) Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). Int J Cancer 111:762–771 Lahmann PH, Hoffmann K, Allen N et al. (2004) Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). Int J Cancer 111:762–771
11.
Zurück zum Zitat Guenel P, Cyr D, Sabroe S, Lynge E, Merletti F, Ahrens W, Baumgardt-Elms C, Menegoz F, Olsson H, Paulsen S, Simonato L, Wingren G (2004) Alcohol drinking may increase risk of breast cancer in men: a European population-based case-control study. Cancer Causes Control 15:571–580 Guenel P, Cyr D, Sabroe S, Lynge E, Merletti F, Ahrens W, Baumgardt-Elms C, Menegoz F, Olsson H, Paulsen S, Simonato L, Wingren G (2004) Alcohol drinking may increase risk of breast cancer in men: a European population-based case-control study. Cancer Causes Control 15:571–580
12.
Zurück zum Zitat Bernstein L, Henderson BE, Hanisch R, Sullivan-Halley J, Ross RK (1994) Physical exercise and reduced risk of breast cancer in young women. J Natl Cancer Inst 86:1403–1408 Bernstein L, Henderson BE, Hanisch R, Sullivan-Halley J, Ross RK (1994) Physical exercise and reduced risk of breast cancer in young women. J Natl Cancer Inst 86:1403–1408
13.
Zurück zum Zitat Fisher B, Jeong JH, Dignam J, Anderson S, Mamounas E, Wickerham DL, Wolmark N (2001) Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr. 30:62–66 Fisher B, Jeong JH, Dignam J, Anderson S, Mamounas E, Wickerham DL, Wolmark N (2001) Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr. 30:62–66
14.
Zurück zum Zitat Veronesi U, Maisonneuve P, Rotmensz N et al. (2003) Italian Tamoxifen Study Group. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 95:160–165 Veronesi U, Maisonneuve P, Rotmensz N et al. (2003) Italian Tamoxifen Study Group. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 95:160–165
15.
Zurück zum Zitat Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, Tidy A, Viggers J, Davey J (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352:98–101 Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, Tidy A, Viggers J, Davey J (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352:98–101
16.
Zurück zum Zitat Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, Hamed A, Howell A, Powles T, IBIS investigators (2002) First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360:817–824 Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, Hamed A, Howell A, Powles T, IBIS investigators (2002) First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360:817–824
17.
Zurück zum Zitat Cuzick J (2003) Aromatase inhibitors in prevention--data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). Recent Results Cancer Res 163:96–103, discussion 264–266, review Cuzick J (2003) Aromatase inhibitors in prevention--data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). Recent Results Cancer Res 163:96–103, discussion 264–266, review
18.
Zurück zum Zitat Tabar L, Yen MF, Vitak B, Chen HH, Smith RA, Duffy SW (2003) Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet 361:1405–1410 Tabar L, Yen MF, Vitak B, Chen HH, Smith RA, Duffy SW (2003) Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet 361:1405–1410
19.
Zurück zum Zitat Perlet C, Heinig A, Prat X, Casselman J, Baath L, Sittek H, Stets C, Lamarque J, Anderson I, Schneider P, Taourel P, Reiser M, Heywang-Kobrunner SH (2002) Multicenter study for the evaluation of a dedicated biopsy device for MR-guided vacuum biopsy of the breast. Eur Radiol 12:1463–1470 Perlet C, Heinig A, Prat X, Casselman J, Baath L, Sittek H, Stets C, Lamarque J, Anderson I, Schneider P, Taourel P, Reiser M, Heywang-Kobrunner SH (2002) Multicenter study for the evaluation of a dedicated biopsy device for MR-guided vacuum biopsy of the breast. Eur Radiol 12:1463–1470
20.
Zurück zum Zitat Early Breast Cancer Trialists‘ Collaborative Group (2002) Multi-agent chemotherapy for early breast cancer. Cochrane Database Syst Rev 1:CD000487, review Early Breast Cancer Trialists‘ Collaborative Group (2002) Multi-agent chemotherapy for early breast cancer. Cochrane Database Syst Rev 1:CD000487, review
21.
Zurück zum Zitat Early Breast Cancer Trialists‘ Collaborative Group (2001) Tamoxifen for early breast cancer. Cochrane Database Syst Rev:CD000486, review Early Breast Cancer Trialists‘ Collaborative Group (2001) Tamoxifen for early breast cancer. Cochrane Database Syst Rev:CD000486, review
22.
Zurück zum Zitat Early Breast Cancer Trialists‘ Collaborative Group (2000) Ovarian ablation for early breast cancer. Cochrane Database Syst Rev 3:CD000485, review Early Breast Cancer Trialists‘ Collaborative Group (2000) Ovarian ablation for early breast cancer. Cochrane Database Syst Rev 3:CD000485, review
23.
Zurück zum Zitat Early Breast Cancer Trialists‘ Collaborative Group (2002) Radiotherapy for early breast cancer. Cochrane Database Syst Rev 2:CD003647, review Early Breast Cancer Trialists‘ Collaborative Group (2002) Radiotherapy for early breast cancer. Cochrane Database Syst Rev 2:CD003647, review
24.
Zurück zum Zitat Roggel F, Hocke S, Lindemann K, Sinz S, Welk A, Bosl M, Pabst M, Nusser N, Braun S, Schmitt M, Harbeck N (2003) Minimal residual disease in breast cancer and gynecological malignancies: phenotype and clinical relevance. Recent Results Cancer Res 162:89–100, review Roggel F, Hocke S, Lindemann K, Sinz S, Welk A, Bosl M, Pabst M, Nusser N, Braun S, Schmitt M, Harbeck N (2003) Minimal residual disease in breast cancer and gynecological malignancies: phenotype and clinical relevance. Recent Results Cancer Res 162:89–100, review
25.
Zurück zum Zitat Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T (2003) The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists‘ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802–1810 Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T (2003) The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists‘ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802–1810
26.
Zurück zum Zitat Coombes RC, Hall E, Gibson LJ et al. (2004) Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081–1092 Coombes RC, Hall E, Gibson LJ et al. (2004) Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081–1092
27.
Zurück zum Zitat Goss PE, Ingle JN, Martino S et al. (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793–1802CrossRefPubMed Goss PE, Ingle JN, Martino S et al. (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793–1802CrossRefPubMed
28.
Zurück zum Zitat Boccardo F (2004) Switching trial of adjuvant tamoxifen with an aromatase inhibitor in postmenopausal patients with breast cancer. Clin Breast Cancer Suppl 1:S13–17 Boccardo F (2004) Switching trial of adjuvant tamoxifen with an aromatase inhibitor in postmenopausal patients with breast cancer. Clin Breast Cancer Suppl 1:S13–17
29.
Zurück zum Zitat Levine MN, Bramwell VH, Pritchard KI et al. (1998) Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16:2651–2658PubMed Levine MN, Bramwell VH, Pritchard KI et al. (1998) Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16:2651–2658PubMed
30.
Zurück zum Zitat French Adjuvant Study Group (2001) Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 19:602–611 French Adjuvant Study Group (2001) Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 19:602–611
31.
Zurück zum Zitat Hutchins L, Green S, Ravdin P et al. (1998) CMF versus CAF with and without tamoxifen in high-risk node.negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: first results of Intergroup Trial INT 002; Proc. ASCO, abstr. # 2 Hutchins L, Green S, Ravdin P et al. (1998) CMF versus CAF with and without tamoxifen in high-risk node.negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: first results of Intergroup Trial INT 002; Proc. ASCO, abstr. # 2
32.
Zurück zum Zitat Piccart MJ, Di Leo A, Beauduin M et al. (2001) Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 19:3103–3110PubMed Piccart MJ, Di Leo A, Beauduin M et al. (2001) Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 19:3103–3110PubMed
33.
Zurück zum Zitat Henderson IC, Berry DA, Demetri GD et al. (2003) Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976–983 Henderson IC, Berry DA, Demetri GD et al. (2003) Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976–983
34.
Zurück zum Zitat Mamounas EP, Bryant J, Lembersky BC, Fisher B, Atkins JN, Fehrenbacher L, Raich PC, Yothers G, Soran N (2003) Wolmark. Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. Proc Am Soc Clin Oncol 22:4, abstr. 12 Mamounas EP, Bryant J, Lembersky BC, Fisher B, Atkins JN, Fehrenbacher L, Raich PC, Yothers G, Soran N (2003) Wolmark. Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. Proc Am Soc Clin Oncol 22:4, abstr. 12
35.
Zurück zum Zitat Nabholtz JM, Pienkowski T, Mackey J et al. (2002) Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 21, abstr. # 141 Nabholtz JM, Pienkowski T, Mackey J et al. (2002) Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 21, abstr. # 141
36.
Zurück zum Zitat Thomssen C, Untch M, Behrens K, Kahlert S, Sattler D, Oberlechner E, Kuhn W, Lebeau A, Dettmer P, Konecny G, Jaenicke F (2000) Randomized trial on dose-intense adjuvant chemotherapy with epirubicin and cyclophosphamide in high-risk breast cancer patients. Breast Cancer Research and Treatment 64, abstr. 319 Thomssen C, Untch M, Behrens K, Kahlert S, Sattler D, Oberlechner E, Kuhn W, Lebeau A, Dettmer P, Konecny G, Jaenicke F (2000) Randomized trial on dose-intense adjuvant chemotherapy with epirubicin and cyclophosphamide in high-risk breast cancer patients. Breast Cancer Research and Treatment 64, abstr. 319
37.
Zurück zum Zitat Citron ML, Berry DA, Cirrincione C, Hudis C et al. (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431–1439CrossRefPubMed Citron ML, Berry DA, Cirrincione C, Hudis C et al. (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431–1439CrossRefPubMed
38.
Zurück zum Zitat Möbus VJ, Untch M, Du Bois A, Lueck HJ, Thomssen C, Kuhn W, Kurbacher C, Nitz U, Kreienberg R, Jackisch C (2004) Dose-dense sequential chemotherapy with epirubicin(E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (= 4 +LN). First results of an AGO-trial. Proc Am Soc Oncol 22 [Suppl 15]:513 Möbus VJ, Untch M, Du Bois A, Lueck HJ, Thomssen C, Kuhn W, Kurbacher C, Nitz U, Kreienberg R, Jackisch C (2004) Dose-dense sequential chemotherapy with epirubicin(E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (= 4 +LN). First results of an AGO-trial. Proc Am Soc Oncol 22 [Suppl 15]:513
39.
Zurück zum Zitat Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN (2004) Is breast cancer survival improving? Cancer 100:44–52 Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN (2004) Is breast cancer survival improving? Cancer 100:44–52
40.
Zurück zum Zitat Rack B, Janni W, Gerber B, Strobl B, Schindlbeck C, Klanner E, Rammel G, Sommer H, Dimpfl T, Friese K (2003) Patients with recurrent breast cancer: does the primary axillary lymph node status predict more aggressive tumor progression? Breast Cancer Res Treat 82:83–92 Rack B, Janni W, Gerber B, Strobl B, Schindlbeck C, Klanner E, Rammel G, Sommer H, Dimpfl T, Friese K (2003) Patients with recurrent breast cancer: does the primary axillary lymph node status predict more aggressive tumor progression? Breast Cancer Res Treat 82:83–92
41.
Zurück zum Zitat Thomssen, Harbeck N, Henselmann B, Prechtl A, Dettmar P, Ulm K, Schmitt M, Graeff H, Jänicke F (1997) Improved estimation of the prognosis in patients with metastatic breast cancer by using the tumorbiological factor PAI-1. Eur Soc Gyn Thomssen, Harbeck N, Henselmann B, Prechtl A, Dettmar P, Ulm K, Schmitt M, Graeff H, Jänicke F (1997) Improved estimation of the prognosis in patients with metastatic breast cancer by using the tumorbiological factor PAI-1. Eur Soc Gyn
42.
Zurück zum Zitat Thomssen C, Janicke F, Harbeck N (2003) Clinical relevance of prognostic factors in axillary node-negative breast cancer. Onkologie 26:438–445, review Thomssen C, Janicke F, Harbeck N (2003) Clinical relevance of prognostic factors in axillary node-negative breast cancer. Onkologie 26:438–445, review
43.
Zurück zum Zitat Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M, German N0 Study Group (2001) Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 93:913–920 Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M, German N0 Study Group (2001) Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 93:913–920
44.
Zurück zum Zitat Harbeck N, Schmitt M, Kates RE, Kiechle M, Zemzoum I, Jänicke F, Thomssen C (2002) Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts. Clin Breast Cancer 3:196–200, review Harbeck N, Schmitt M, Kates RE, Kiechle M, Zemzoum I, Jänicke F, Thomssen C (2002) Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts. Clin Breast Cancer 3:196–200, review
45.
Zurück zum Zitat van ‚t Veer LJ, Dai H, van de Vijver MJ et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536CrossRefPubMed van ‚t Veer LJ, Dai H, van de Vijver MJ et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536CrossRefPubMed
46.
Zurück zum Zitat Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100:10393–10398, Epub Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100:10393–10398, Epub
47.
Zurück zum Zitat Maier S, Nimmrich I, Marx A, Eppenberger-Castori S, Jaenicke F, Paradiso A, Spyratos F, Foekens J, Schmitt M, Harbeck N (2004) DNA methylation profile predicts risk of recurrence in tamoxifen-treated, node-negative breast cancer patients. J Clin Oncol, ASCO Annual Meeting Proceedings 22 [Suppl]:2004:525 Maier S, Nimmrich I, Marx A, Eppenberger-Castori S, Jaenicke F, Paradiso A, Spyratos F, Foekens J, Schmitt M, Harbeck N (2004) DNA methylation profile predicts risk of recurrence in tamoxifen-treated, node-negative breast cancer patients. J Clin Oncol, ASCO Annual Meeting Proceedings 22 [Suppl]:2004:525
48.
Zurück zum Zitat Leitlinie zur Diagnostik und Therapie von Mammakarzinomen. Version 2004 Organkommission Mamma der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO)(in Zusammenarbeit mit der ARO). http://www.ago-online.org Leitlinie zur Diagnostik und Therapie von Mammakarzinomen. Version 2004 Organkommission Mamma der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO)(in Zusammenarbeit mit der ARO). http://​www.​ago-online.​org
Metadaten
Titel
Mammakarzinom—Standards der Versorgung heute und morgen
verfasst von
Prof. Dr. C. Thomssen
Publikationsdatum
01.03.2005
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 3/2005
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-005-0835-3

Weitere Artikel der Ausgabe 3/2005

Der Onkologe 3/2005 Zur Ausgabe

Aktuelle Onkologie

Wendekreis des Krebses

Neu im Fachgebiet Onkologie

Verkürzte MRT bei dichtem Brustgewebe: Was bringen sequenzielle Scans?

21.07.2024 Mamma-MRT Nachrichten

Frauen mit dichtem Brustgewebe könnten zusätzlich zum regulären Mammografie-Screening von sequenziellen MRT-Untersuchungen mit verkürztem Protokoll (AB-MRT) profitieren, schlagen US-Radiologen vor.

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Endometriose-Subtypen und das Risiko für Ovarialkarzinome

19.07.2024 Ovarialkarzinom Nachrichten

US-Kohortendaten sprechen dafür, dass verschiedene Endometrioseformen unterschiedlich mit dem Risiko für Ovarialkarzinome assoziiert sind. Besonders erhöht ist das Risiko offenbar bei tief infiltrierenden und ovariellen Endometrioseformen.

Die zelluläre Differenzierung wird wiederhergestellt

18.07.2024 Akute myeloische Leukämie Nachrichten

Ivosidenib von Servier ist ein Inhibitor der mutierten Isoform der Isocitrat-Dehydrogenase-1 (IDH1) und wird zur Behandlung von Patientinnen und Patienten mit neu diagnostizierter akuter myeloischer Leukämie (AML) eingesetzt. Die Substanz sorgt für die Wiederherstellung der zellulären Differenzierung.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.